Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection. What will really matter in the long run? That’s the question we tackle each year as ...

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

In a ceremony held last month, the 2024 Louisa Gross Horwitz Prize was awarded to Wesley Sundquist, PhD, Leo T. and Barbara K ...

On February 18, 2025, Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications ...

The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and ...

To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

来自吉利德科学公司（Gilead Sciences）的药物研究人员宣布，他们开发的 艾滋病 毒（HIV）预防药物来那卡帕韦（lenacapavir）的新配方使其在人体内存留长达一年的时间。在发表在 Lancet 杂志上的论文中，他们描述了他们如何将这种新配方注射到几名没有感染HIV的志愿者身上，并对他们进行了长达一年的测试，以及他们在这一过程中发现了什么。

A NEW injection that could prevent HIV infection has successfully completed an early safety trial, according to a report in ...

A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...

吉利德科学宣布了一个重要的里程碑：美国FDA接受了lenacapavir （LEN）的新药申请（NDAs）， lenacapavir （LEN）是一种突破性的每年两次注射的HIV-1衣壳抑制剂，用于暴露前预防（PrEP）。